Viatris to Acquire Pacira BioSciences for $1.65 Billion to Expand Pain Management Segment

Key numbers

Deal value	$1.6B
Share of market cap	8.2%
Share of annual revenue	11.5%

Key highlights

• Cash tender offer of $36.50 per share representing a $1.65 billion aggregate equity value
• Acquisition adds patent-protected medicines EXPAREL and ZILRETTA to Viatris' portfolio
• Transaction expected to be immediately accretive to Viatris' financial guidance metrics
• Viatris plans to fund the deal through excess cash and short-term debt
• Pacira reported $746 million in total revenue for the twelve months ended June 30, 2026

What Is the Deal?

Viatris Inc. has entered into a definitive agreement to acquire Pacira BioSciences, Inc. for $36.50 per share in cash. The transaction, representing an aggregate equity value of approximately $1.65 billion, aims to establish Viatris as a leader in the non-opioid pain therapy market. This acquisition follows a series of recent portfolio adjustments by Viatris, including the divestiture of its equity stake in Biocon Biologics for $815 million in late 2025 and its Tyrvaya product rights for $30 million in August 2026. The deal is expected to conclude by the end of 2026, following the completion of a tender offer.

Deal Structure & Terms

• Structured as a tender offer followed by a merger under Section 251(h) of the DGCL
• Cash consideration of $36.50 per share, net of applicable withholding taxes
• Minimum condition requires more than 50% of outstanding common stock to be tendered
• Funded primarily through excess cash with remaining balance from short-term borrowings
• No financing condition is required for the consummation of the offer

Strategic Rationale

“The addition of EXPAREL, for acute postsurgical pain, and ZILRETTA, for osteoarthritis knee pain, are synergistic with our fast-acting meloxicam market opportunity and position us as a leader in non-opioid pain management therapies, an area where patients and healthcare providers continue to seek more treatment options.”

Financial Context

The acquisition is projected to be immediately accretive to Viatris' financial guidance metrics upon closing. Pacira reported total revenue of approximately $746 million and adjusted EBITDA of $177 million for the twelve months ended June 30, 2026. Viatris, which maintains a market capitalization of approximately $20.09 billion and annual revenue of $14.3 billion, intends for the transaction to have minimal impact on its gross leverage ratio. The company is also awaiting an FDA PDUFA decision on October 17, 2026, for MR-141, highlighting a period of active pipeline development alongside this major inorganic expansion.

Down 1.4% since our story on 8 Oct: $17.49 when we broke it → $17.25 at the close on 13 Oct. Daily closing prices. Source: Yahoo Finance.

Show the prices

14 Sep	$16.66
15 Sep	$16.65
16 Sep	$17.02
17 Sep	$17.13
18 Sep	$16.95
21 Sep	$17.10
22 Sep	$17.18
23 Sep	$17.12
24 Sep	$17.42
25 Sep	$17.83
28 Sep	$18.27
29 Sep	$18.12
30 Sep	$17.72
1 Oct	$17.46
2 Oct	$17.60
5 Oct	$17.62
6 Oct	$17.54
7 Oct	$17.49
8 Oct	$17.44
9 Oct	$17.64
12 Oct	$17.54
13 Oct	$17.25

Industry Landscape

• Shift toward non-opioid pain management solutions driven by evolving public health standards
• Increasing consolidation in specialty pharmaceuticals to leverage existing global distribution
• Growing importance of patent-protected, high-margin assets in sustaining revenue growth
• Strategic utilization of divestiture proceeds from non-core assets to fund specialty acquisitions

Management commentary

“The pending acquisition of Pacira BioSciences is an important step in advancing our strategy to build our innovative medicines business.”

“Importantly, we expect to fund the transaction primarily from excess cash with the remainder from short-term borrowings. As such, we expect the transaction will have minimal impact on our gross leverage ratio.”

Viatris Inc · financial snapshot

Share price	$17.49
Market cap	$20.1B
Revenue (annual)	$14.3B
1-month price change	+3.61%
Sector	HealthcareDrug Manufacturers - Specialty & Generic

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.